FDA orphan drug defeat has important implications for exclusivity
Agency acted in a way that was “arbitrary, capricious and not in accordance with the law” over treatment for rare disease developed by Catalyst Pharmaceuticals, says 11th Circuit appellate court
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.